These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16753757)

  • 1. Invasive and non-invasive investigations for tamoxifen-induced non-alcoholic steatohepatitis (NASH): the benefit of computed tomography scan guided liver biopsy.
    Ahmed MH; Osman KA; Osman MM
    Pathology; 2006 Jun; 38(3):270-1. PubMed ID: 16753757
    [No Abstract]   [Full Text] [Related]  

  • 2. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis.
    Murata Y; Ogawa Y; Saibara T; Nishioka A; Takeuchi N; Kariya S; Onishi S; Yoshida S
    Oncol Rep; 2003; 10(1):97-100. PubMed ID: 12469151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate.
    Ogawa Y; Murata Y; Saibara T; Nishioka A; Kariya S; Yoshida S
    Oncol Rep; 2003; 10(5):1473-8. PubMed ID: 12883726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen].
    Dray X; Tainturier MH; De La Lande P; Marty O; Mallet L
    Gastroenterol Clin Biol; 2000 Nov; 24(11):1122-3. PubMed ID: 11139682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer.
    Nguyen MC; Stewart RB; Banerji MA; Gordon DH; Kral JG
    Int J Obes Relat Metab Disord; 2001 Feb; 25(2):296-8. PubMed ID: 11410835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
    Bruno S; Maisonneuve P; Castellana P; Rotmensz N; Rossi S; Maggioni M; Persico M; Colombo A; Monasterolo F; Casadei-Giunchi D; Desiderio F; Stroffolini T; Sacchini V; Decensi A; Veronesi U
    BMJ; 2005 Apr; 330(7497):932. PubMed ID: 15746106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Histopathological diagnose of non-alcoholic and alcoholic fatty liver disease].
    Tannapfel A; Denk H; Dienes HP; Langner C; Schirmacher P; Trauner M; Flott-Rahmel B
    Z Gastroenterol; 2010 Apr; 48(4):486-98. PubMed ID: 20352596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of ultrasonography and computerized tomography in estimating the histopathological severity of nonalcoholic steatohepatitis.
    Ataseven H; Yildirim MH; Yalniz M; Bahcecioglu IH; Celebi S; Ozercan IH
    Acta Gastroenterol Belg; 2005; 68(2):221-5. PubMed ID: 16013637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist.
    Ahmed MH; Osman KA
    Breast Cancer Res Treat; 2006 May; 97(2):223-4. PubMed ID: 16322887
    [No Abstract]   [Full Text] [Related]  

  • 10. Tamoxifen-induced transient multifocal hepatic fatty infiltration.
    Cai Q; Bensen M; Greene R; Kirchner J
    Am J Gastroenterol; 2000 Jan; 95(1):277-9. PubMed ID: 10638597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty liver and drugs.
    Grieco A; Forgione A; Miele L; Vero V; Greco AV; Gasbarrini A; Gasbarrini G
    Eur Rev Med Pharmacol Sci; 2005; 9(5):261-3. PubMed ID: 16237810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of fatty liver disease: is biopsy necessary?
    Joy D; Thava VR; Scott BB
    Eur J Gastroenterol Hepatol; 2003 May; 15(5):539-43. PubMed ID: 12702913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Education and imaging: hepatobiliary and pancreatic: focal steatohepatitis mimicking a metastasis.
    Choi JS; Kim MJ
    J Gastroenterol Hepatol; 2011 Feb; 26(2):415. PubMed ID: 21261737
    [No Abstract]   [Full Text] [Related]  

  • 14. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients.
    Ohnishi T; Ogawa Y; Saibara T; Nishioka A; Kariya S; Fukumoto M; Onishi S; Yoshida S
    Oncol Rep; 2005 Mar; 13(3):485-9. PubMed ID: 15706422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug-induced NASH].
    Saibara T; Onishi S
    Nihon Rinsho; 2006 Jun; 64(6):1100-5. PubMed ID: 16768116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?
    Osman KA; Osman MM; Ahmed MH
    Expert Opin Drug Saf; 2007 Jan; 6(1):1-4. PubMed ID: 17181445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis.
    Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
    Lancet; 1999 May; 353(9166):1802. PubMed ID: 10348023
    [No Abstract]   [Full Text] [Related]  

  • 18. Tamoxifen-induced fatty liver in patients with breast cancer.
    Ogawa Y; Murata Y; Nishioka A; Inomata T; Yoshida S
    Lancet; 1998 Mar; 351(9104):725. PubMed ID: 9504521
    [No Abstract]   [Full Text] [Related]  

  • 19. [Diagnostic criteria for non-alcoholic steatohepatitis].
    Hashimoto E
    Nihon Rinsho; 2006 Jun; 64(6):1025-32. PubMed ID: 16768105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology and biopsy assessment of non-alcoholic fatty liver disease.
    Straub BK; Schirmacher P
    Dig Dis; 2010; 28(1):197-202. PubMed ID: 20460911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.